Maprotiline Ameliorates High Glucose-Induced Dysfunction in Renal Glomerular Endothelial Cells

Abstract

Maprotiline is an antidepressant that has been found to cause hypoglycemia. However, the effect of maprotiline on diabetic nephropathy (DN) has not been investigated. Here, we explored the effect of maprotiline on human renal glomerular endothelial cells (HRGECs) in response to high glucose (HG) stimulation. We found that maprotiline attenuated HG-induced oxidative stress in HRGECs with decreased reactive oxygen species production and increased superoxide dismutase activity. Maprotiline repressed the HG-induced expression of cyclooxygenases 2 at both mRNA and protein levels in HRGECs. The increased thromboxane B2 level and decreased 6-keto-prostaglandin F1α level induced by HG were significantly attenuated by maprotiline treatment. Maprotiline also prevented the HG-induced increase in the permeability of HRGECs and the decrease in the zonula occludens-1 expression and downregulated HG-induced increase in the expression of protein kinase C-α (PKC-α) in HRGECs. This protective effect of maprotiline on HG-induced HRGECs dysfunction was abolished by overexpression of PKC-α. In conclusion, maprotiline displayed a protective effect on HG-challenged HRGECs, which was mediated by the regulation of PKC-α. These findings provide further evidence for the potential use of maprotiline for the treatment of DN.

Key words

Maprotiline - diabetic nephropathy (DN) - oxidative stress - inflammation - permeability - protein kinase C (PKC)

^* Contributed equally to this work

Publikationsverlauf

Eingereicht: 13. August 2021
Eingereicht: 03. November 2021

Angenommen: 30. November 2021

Artikel online veröffentlicht:
23. März 2022

• References

• 1 Lu Y, Liu D, Feng Q. et al. Diabetic nephropathy: Perspective on extracellular vesicles. Front Immunol 2020; 11: 943
• 2 Zheng S, Powell DW, Zheng F. et al. Diabetic nephropathy: Proteinuria, inflammation, and fibrosis. J Diabetes Res 2016; 2016: 5241549
• 3 Tonneijck L, Muskiet MH, Smits MM. et al. Glomerular hyperfiltration in diabetes: Mechanisms, clinical significance, and treatment. J Am Soc Nephrol 2017; 28: 1023-1039
• 4 Sagoo MK, Gnudi L. Diabetic nephropathy: An overview. Methods Mol Biol 2020; 2067: 3-7
• 5 Daehn IS, Duffield JS. The glomerular filtration barrier: A structural target for novel kidney therapies. Nat Rev Drug Discov 2021; 1-19
• 6 Ebefors K, Lassen E, Anandakrishnan N. et al. Modeling the glomerular filtration barrier and intercellular crosstalk. Front Physiol 2021; 12: 689083
• 7 Chen SJ, Lv LL, Liu BC. et al. Crosstalk between tubular epithelial cells and glomerular endothelial cells in diabetic kidney disease. Cell Prolif 2020; 53: e12763
• 8 Fu J, Lee K, Chuang PY. et al. Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol 2015; 308: F287-F297
• 9 Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 2013; 124: 139-152
• 10 Donate-Correa J, Luis-Rodriguez D, Martin-Nunez E. et al. Inflammatory targets in diabetic nephropathy. J Clin Med 2020; 9: 458
• 11 Brown LC, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract 2008; 79: 61-67
• 12 Andersohn F, Schade R, Suissa S. et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-598
• 13 Atlantis E, Browning C, Sims J. et al. Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA). Int J Geriatr Psychiatry 2010; 25: 688-696
• 14 Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm 2011; 33: 484-492
• 15 Parra A, Martos A, Monleon S. et al. Effects of acute and chronic maprotiline administration on inhibitory avoidance in male mice. Behav Brain Res 2000; 109: 1-7
• 16 Isotani H, Kameoka K. Hypoglycemia associated with maprotiline in a patient with type 1 diabetes. Diabetes Care 1999; 22: 862-863
• 17 Zogno MG, Tolfo L, Draghi E. Hypoglycemia caused by maprotiline in a patient taking oral antidiabetics. Ann Pharmacother 1994; 28: 406
• 18 Chen YC, Shen YC, Hung YJ. et al. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord 2007; 103: 257-261
• 19 Pinar M, Gulsun M, Tasci I. et al. Maprotiline induced weight gain in depressive disorder: Changes in circulating ghrelin and adiponectin levels and insulin sensitivity. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 135-139
• 20 Lee WC, Chau YY, Ng HY. et al. Empagliflozin protects HK-2 cells from high glucose-mediated injuries via a mitochondrial mechanism. Cells 2019; 8: 1085
• 21 Rafiee L, Hajhashemi V, Javanmard SH. Maprotiline inhibits LPS-induced expression of adhesion molecules (ICAM-1 and VCAM-1) in human endothelial cells. Res Pharm Sci 2016; 11: 138-144
• 22 Gao F, Zhang S. Loratadine alleviates advanced glycation end product-induced activation of NLRP3 inflammasome in human chondrocytes. Drug Des Devel Ther 2020; 14: 2899-2908
• 23 Liu X, Wang B, Ding H. et al. Low-intensity pulsed ultrasound in combination with SonoVue induces cytotoxicity of human renal glomerular endothelial cells via repression of the ERK1/2 signaling pathway. Ren Fail 2018; 40: 458-465
• 24 Kalani A, Kamat PK, Chaturvedi P. et al. Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. Life Sci 2014; 107: 1-7
• 25 Dowlati Y, Herrmann N, Swardfager W. et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457
• 26 Pal SN, Dandiya PC. Glutathione as a cerebral substrate in depressive behavior. Pharmacol Biochem Behav 1994; 48: 845-851
• 27 Maes M, Song C, Lin AH. et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999; 20: 370-379
• 28 Rafiee L, Hajhashemi V, Javanmard SH. Maprotiline inhibits COX2 and iNOS gene expression in lipopolysaccharide-stimulated U937 macrophages and carrageenan-induced paw edema in rats. Cent Eur J Immunol 2019; 44: 15-22
• 29 Sadeghi H, Hajhashemi V, Minaiyan M. et al. Further studies on anti-inflammatory activity of maprotiline in carrageenan-induced paw edema in rat. Int Immunopharmacol 2013; 15: 505-510
• 30 Kruger-Genge A, Blocki A, Franke RP. et al. Vascular endothelial cell biology: An update. Int J Mol Sci 2019; 20: 4411
• 31 Sakai K, Ito K, Ogawa K. Roles of endogenous prostacyclin and thromboxane A2 in the ischemic canine heart. J Cardiovasc Pharmacol 1982; 4: 129-135
• 32 Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978; 30: 293-331
• 33 Zhang J, Feng Y, Li S. et al. Microvascular pathological features and changes in related injury factors in a rat acute blood stasis model. J Tradit Chin Med 2017; 37: 108-115
• 34 Knapp M, Tu X, Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. Acta Pharmacol Sin 2019; 40: 1-8
• 35 Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106: 1319-1331
• 36 Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev 2008; 88: 1341-1378
• 37 Haller H. Postprandial glucose and vascular disease. Diabet Med 1997; 14: S50-S56
• 38 Lynch JJ, Ferro TJ, Blumenstock FA. et al. Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin Invest 1990; 85: 1991-1998